DNL Diurnal Group Plc

TIDMDNL

RNS Number : 3760E

Diurnal Group PLC

07 July 2021

07 July 2021

Diurnal Group plc

("Diurnal" or the "Company")

Notice of Full Year Results and Adoption of Financial Reporting Standard ("FRS") 101

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2021 on Tuesday, 14 September 2021.

Diurnal Group plc has elected to adopt FRS 101, Reduced Disclosure Framework, under the UK Generally Accepted Accounting Practice ("GAAP") accounting framework for the preparation of its parent and UK subsidiary company financial statements for the year ended 30 June 2021 and on an ongoing basis until such time as shareholders are notified of any change, primarily to reduce duplicated disclosures in its UK subsidiary company financial statements. Diurnal Group plc's election to adopt FRS 101 for its parent and UK subsidiary company financial statements does not require shareholder approval. However, as stipulated in FRS 101, Diurnal is required to notify all shareholders of this election. Any shareholder or shareholders holding in aggregate 5% or more of the total allotted shares in Diurnal Group plc may serve an objection to the use of the disclosure exemptions. Objections must be served in writing and delivered to the Company Secretary at Diurnal Group plc, Cardiff Medicentre, Heath Park, Cardiff, CF14 4UJ, UK, no later than one month from the date of this announcement.

 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                   +44 (0)20 3727 
 Diurnal Group plc                                  1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    +44 (0)20 7886 
  and Sole Broker)                                  2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: Rupert Dearden 
 
                                                   +44 (0)20 3727 
 FTI Consulting (Media and Investor Relations)      1000 
 Simon Conway 
 Victoria Foster Mitchell 
 Alex Davis 
 

Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFFFELDVIRIIL

(END) Dow Jones Newswires

July 07, 2021 02:00 ET (06:00 GMT)

Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024